On Thursday, the U.S. Food and Drug Administration (FDA) made permanent its April 2021 order that removed the required in-person doctor’s visit for women seeking a chemical abortion. Today’s decision by the FDA allows the abortion pills, mifepristone and misoprostol, to be distributed by mail after a woman has a telehealth call with an abortion provider.
“The FDA’s decision today places women at risk,” said Carol Tobias, President of the National Right to Life Committee. “These changes do not make this abortion process safer for women. What these changes do is make the process easier for the abortion industry.”
Continued Tobias, “The FDA knows the dangers of this abortion drug combination, but in the name of political expediency, has lifted the safety measure requiring an in-person doctor’s visit.”
The FDA has a record of nearly two dozen deaths and thousands of complications associated with the use of the mifepristone/misoprostol abortion-drug combination. These dangerous pills have documented “adverse events” including serious infections and severe hemorrhaging. The FDA has had limits on distribution of mifepristone since its approval in September of 2000 and has placed the drug under a special “risk evaluation and mitigation strategy” or REMS that it has for drugs that may be associated with life-threatening side effects.